Amarin (NASDAQ:AMRN) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Amarin (NASDAQ:AMRN) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02), Zacks reports. The company had revenue of $42.30 million during the quarter, compared to analyst estimates of $43.82 million. Amarin had a negative net margin of 16.33% and a negative return on equity of 7.15%. During the same quarter last year, the business earned ($0.05) EPS.

Amarin Stock Up 1.1 %

Shares of Amarin stock traded up $0.01 during trading on Friday, hitting $0.59. The stock had a trading volume of 803,613 shares, compared to its average volume of 1,547,164. Amarin has a 1 year low of $0.56 and a 1 year high of $1.37. The stock has a 50 day simple moving average of $0.60 and a 200 day simple moving average of $0.71. The company has a market capitalization of $240.73 million, a PE ratio of -6.51 and a beta of 1.92.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.